CEL-SCI Corp. CVM 深 沪
已收盘 08-01 16:00:00 美东时间
9.45
+1.270
+15.53%
华盛通- 最 高9.50
- 今 开8.07
- 成交量 54.77万股
- 最 低 7.75
- 昨 收 8.18
- 总市值 4852.58万
- 52周最高 39.30
- 市盈率 静 --
- 换手率 10.67%
- 52周最低 1.98
- 委 比 -33.33%
- 总股本 513.50万
- 历史最高 1425.00
- 量 比 0.60
- 振 幅 21.39%
- 历史最低 5.40
- 每 手 1
- 风险率 11.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
这就是牛市！珍惜高确定性投资主线的回调机会！
7月23日，上证指数盘中最高触及3613.02点，再次刷新年内新高；7月22日，恒生指数收于25000点之上，并于7月24日盘中触及25735.89点，创下了逾...
07-26 13:20
BRF S.A. Postpones Extraordinary General Meeting Again Amid Regulatory Scrutiny
BRF SA ( ($BRFS) ) just unveiled an update. On July 11, 2025, BRF S.A. announce...
07-12 05:27
CEL-SCI announces pricing of $5.7 million offering
CEL-SCI (NYSE:CVM) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share,...
07-12 03:04
CEL-SCI Signs Partnership Agreement With Saudi Arabian Pharma And Healthcare Company On Regulatory And Commercial Activities For Multikine In Kingdom Of Saudia Arabia
Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa marketPatient access and reimbursement/sale in Saudi Arabia within
07-11 21:18
Ambev S.A. Reports June 2025 Securities Transactions
Ambev SA ( ($ABEV) ) has issued an announcement. In June 2025, Ambev S.A. repor...
07-09 05:27
信达生物（01801.HK）7月7日收盘跌4.23%，主力资金净流出1.73亿港元
证券之星消息，截至2025年7月7日收盘，信达生物(01801.HK)报收于82.55港元，下跌4.23%，成交量2382.37万股，成交额19.94亿港元。
07-07 17:56
CEL-SCI Highlights FDA Approval Of Merck's Keytruda As Precedent For Multikine, Citing 66% Reduction In Risk Of Death In Low/Zero PD-L1 Head And Neck Cancer Patients vs. Keytruda's 30% Recurrence Reduction In PD-L1 Positive Tumors
FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approvalMultikine reduced the risk of death by 66% compared to standard of care in the target
06-18 21:19
信达生物（01801.HK）6月3日收盘涨3.09%，主力资金净流入3284.67万港元
证券之星消息，截至2025年6月3日收盘，信达生物(01801.HK)报收于65.05港元，上涨3.09%，成交量2312.65万股，成交额14.97亿港元。
06-03 18:16
Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Urban Outfitters, Inc. (NASDAQ:URBN) rose sharply in today's pre-mark...
05-22 17:30
